Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality.

The American journal of pathology - 1 Feb 2005

Li Zhi-Fang, Shelton G Diane, Engvall Eva

Abstract excerpt

Myostatin is a TGF-beta family member and a negative regulator of skeletal muscle growth. It has been proposed that reduction or elimination of myostatin could be a treatment for degenerative muscle diseases such as muscular dystrophy. Laminin-deficient congenital muscular dystrophy is one of the most severe forms of muscular dystrophy. To test the possibility of ameliorating the dystrophic phenotype in laminin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipocytes
Share to Adipose Tissue
Share to Laminin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Mutant Strains

Share to Muscle Fibers, Skeletal

Share to Muscular Dystrophies

Share to Myostatin

Share to Transforming Growth Factor beta

Source

Open in PubMed Open full text

Identifiers

PMID: 15681832
DOI: 10.1016/S0002-9440(10)62271-7
PMCID: PMC1602316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality.PMID 15681832Read ↗

Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy.Semantic proximity Read ↗

Early skeletal muscle pathology and disease progress in the dy3K/dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiencySemantic proximity Read ↗

Expression of myostatin pro domain results in muscular transgenic mice.Semantic proximity Read ↗

Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.Semantic proximity Read ↗

Loss of dystrophin and β-sarcoglycan significantly exacerbates the phenotype of laminin α2 chain-deficient animals.Semantic proximity Read ↗

Myostatin blockade improves function but not histopathology in a murine model of limb‐girdle muscular dystrophy 2CSemantic proximity Read ↗

Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects.Semantic proximity Read ↗

The elusive promise of myostatin inhibition for muscular dystrophy.Semantic proximity Read ↗

Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsSemantic proximity Read ↗

Satellite cell depletion in early adulthood attenuates muscular dystrophy pathogenesisSemantic proximity Read ↗

Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.Semantic proximity Read ↗

The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.